Company Renascience Inc.

4889

JP3981100005

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:19:46 2024-04-29 pm EDT			5-day change	1st Jan Change
346 ^JPY	-0.29%		+0.87%	-20.28%

2022	Certain Common Stock of Renascience Inc. are subject to a Lock-Up Agreement Ending on 22-MAR-2022.	CI
2021	Certain Common Stock of Renascience Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2021.	CI

Renascience Inc is mainly engaged in the development and sale of pharmaceuticals and medical devices. The company is engaged in the research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI) solutions) to solve problems in the medical field, in collaboration with physicians. The Company is engaged in the development of drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The Company is also engaged in the solve of other medical issues such as diseases of women and children, and COVID-19 infection.

Number of employees: 3

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals, Medical Devices, Etc. 100.0 %	139	100.0 %	101	100.0 %	-27.84%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	139	100.0 %	101	100.0 %	-27.84%

Managers	Title	Age	Since
Koji Naito PSD	President	65	18-12-31
Sho Kato CTO	Chief Tech/Sci/R&D Officer	35	18-04-30
Kazuhiro Ikeda ADM	Chief Administrative Officer	68	19-12-31

Members of the board	Title	Age	Since
Yasuo Azuma BRD	Director/Board Member	76	19-03-31
Kazuhiro Ikeda ADM	Chief Administrative Officer	68	19-12-31
Toshio Miyata CHM	Chairman	63	18-03-31
Koji Naito PSD	President	65	18-12-31
Sho Kato CTO	Chief Tech/Sci/R&D Officer	35	18-04-30
Mitsuru Ichikawa BRD	Director/Board Member	64	19-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	12,711,700	6,130,800 ( 48.23 %)	0	48.23 %

Name	Equities	%	Valuation
Toshio Miyata 11.17 %	1,420,000	11.17 %	4 M ¥
DCI Partners KK 9.895 %	1,257,800	9.895 %	3 M ¥
Ueda Yagi Tanshi Co., Ltd. 2.039 %	259,200	2.039 %	652 518 ¥
SMBC Venture Capital KK 1.180 %	150,000	1.180 %	377 615 ¥
Takeo Komase 0.5231 %	66,500	0.5231 %	167 409 ¥
77 Capital KK 0.4814 %	61,200	0.4814 %	154 067 ¥
OTSUKA HOLDINGS CO., LTD. 0.2879 %	36,600	0.2879 %	92 138 ¥
TOHOKU CHEMICAL CO., LTD. 0.2360 %	30,000	0.2360 %	75 523 ¥
DAIICHI SANKYO CO., LTD. 0.2360 %	30,000	0.2360 %	75 523 ¥

Renascience, Inc.

Kyodo Building 401 2-3-6 Nihonbashi Honcho

103-0023, Tokyo

http://www.renascience.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
RENASCIENCE INC.	-20.28%	28.02M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Other Pharmaceuticals